Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2019 Genitourinary Cancers Symposium /
ASCO GU 2019: Treatment and management of hormone-sensitive metastatic prostate cancer

14th - 16th Feb 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.03.19
Views: 3247

Prof Karim Fizazi, Dr Eleni Efstathiou

Professor Karim Fizazi and Professor Eleni Efstathiou set the scene in current care and discuss the treatment options available for hormone-sensitive metastatic prostate cancer, highlighting the unmet need in recurrent metastatic disease.

New updates to the outcomes of the STAMPEDE, ARCHES, and LATITUDE studies presented at ASCO GU 2019 are also reviewed.

Finally, Professors Fizazi and Efstathiou consider the need for longer term efficacy and safety data for enzalutamide.

Summary of the results obtained from the CHAARTED trial
Outcomes achieved in the STAMPEDE trial
Assessment of enzalutamide in the ARCHES trial
Overall survival in the LATITUDE trial
Strategies for more targeted therapies

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation